Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/22895
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYıldırım, Volkan-
dc.contributor.authorOmak, M.-
dc.contributor.authorKara, Hasan-
dc.contributor.authorTüfekçi, M. A.-
dc.date.accessioned2021-11-30T13:31:54Z-
dc.date.available2021-11-30T13:31:54Z-
dc.date.issued2001-02-
dc.identifier.citationOzan, H. vd. (2002). "Misoprostol in labor induction". Journal of Obstetrics and Gynaecology Research, 27(1), 17-20.tr_TR
dc.identifier.issn1341-8076-
dc.identifier.urihttps://doi.org/10.1111/j.1447-0756.2001.tb01209.x-
dc.identifier.urihttps://obgyn.onlinelibrary.wiley.com/doi/10.1111/j.1447-0756.2001.tb01209.x-
dc.identifier.urihttp://hdl.handle.net/11452/22895-
dc.description.abstractThe efficacy of a new dosing regimen of misoprostol, a recently introduced labor-inducing agent, was studied. Fifty-eight patients received 50 mug of misoprostol intravaginally and the dose was repeated every 3 hours until uterine contractions begin. Those who had an adequate contraction pattern, defined as three contractions in 10 minutes, were not given the repeat dose. Oxytocin augmentation, but not further misoprostol doses, was used in patients with an inadequate contraction pattern. The maximum total daily dose was 200 mug. The patients had the mean age of 28.9 +/- 5.4, the mean gestational age of 211.8 +/- 46.6 days, the mean gravidity of 2.5 +/- 1.2, the mean parity of 0.9 +/- 0.9 and the mean initial Bishop score of 1.6 +/- 1.8. The mean required dose of misoprostol was 120.5 +/- 54.7 mug and 10 of 58 patients required oxytocin augmentation. The mean induction of labor to delivery time was 701.5 +/- 404.0 minutes. When 3 cases who gave birth with caesarean section were excluded, the interval was 708.4 +/- 407.2 minutes. The mean 5th minute Apgar score of the newborns was 8.2 +/- 2.5. Two patients developed tachysystole after the second dose of misoprostol and were managed with vaginal irrigation and 02 supplementation successfully. Slight nausea and vomiting in 2 patients were the other adverse reactions. Our findings revealed that, 50 mug intravaginal misoprostol, combined with oxytocin augmentation when necessary, appears to be an effective and safe method of labor inductiontr_TR
dc.language.isoentr_TR
dc.publisherWileytr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCervical ripeningtr_TR
dc.subjectLabor inductiontr_TR
dc.subjectMisoprostoltr_TR
dc.subjectProstaglandin E(2) geltr_TR
dc.subjectIntravaginal misoprostoltr_TR
dc.subjectObstetrics & gynecologytr_TR
dc.titleMisoprostol in labor inductiontr_TR
dc.typeArticletr_TR
dc.identifier.wos000173333500002tr_TR
dc.identifier.scopus2-s2.0-0035083408tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı.tr_TR
dc.identifier.startpage17tr_TR
dc.identifier.endpage20tr_TR
dc.identifier.volume27tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalJournal of Obstetrics and Gynaecology Researchtr_TR
dc.contributor.buuauthorOzan, Hakan-
dc.contributor.buuauthorUncu, Gürkan-
dc.relation.collaborationYurtiçitr_TR
dc.identifier.pubmed11330725tr_TR
dc.subject.wosObstetrics & gynecologytr_TR
dc.indexed.wosSCIEtr_TR
dc.indexed.scopusScopustr_TR
dc.indexed.pubmedPubmedtr_TR
dc.contributor.scopusid7003908072tr_TR
dc.contributor.scopusid6603716169tr_TR
dc.contributor.scopusid7003802609tr_TR
dc.contributor.scopusid6507305700tr_TR
dc.contributor.scopusid57206375401tr_TR
dc.contributor.scopusid6602656874tr_TR
dc.subject.scopusInduced Labor; Cervical Ripening; Misoprostoltr_TR
dc.subject.emtreeClinical trialtr_TR
dc.subject.emtreeMisoprostoltr_TR
dc.subject.emtreeOxytocintr_TR
dc.subject.emtreeApgar scoretr_TR
dc.subject.emtreeArticletr_TR
dc.subject.emtreeCesarean sectiontr_TR
dc.subject.emtreeDose responsetr_TR
dc.subject.emtreeCost effectiveness analysistr_TR
dc.subject.emtreeDeliverytr_TR
dc.subject.emtreeDrug costtr_TR
dc.subject.emtreeDrug efficacytr_TR
dc.subject.emtreeDrug mechanismtr_TR
dc.subject.emtreeDrug safetytr_TR
dc.subject.emtreeDrug tolerabilitytr_TR
dc.subject.emtreeFemaletr_TR
dc.subject.emtreeOxygen therapytr_TR
dc.subject.emtreeHeart arrhythmiatr_TR
dc.subject.emtreeHumantr_TR
dc.subject.emtreeNausea and vomitingtr_TR
Appears in Collections:Web of Science

Files in This Item:
File Description SizeFormat 
Ozan_vd_2001.pdf338.36 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons